肠道菌群在代谢、免疫疾病中作用的研究进展
Research Progress of Gut Microbiota’s Function in Metabolic and Immunological Diseases
DOI: 10.12677/OJNS.2022.106107, PDF,    科研立项经费支持
作者: 孙 卓:西安医学院,西安市病原微生物与肿瘤免疫重点实验室,陕西 西安;西安医学院,基础医学研究所,陕西 西安
关键词: 肠道菌群代谢疾病免疫疾病Gut Microbiota Metabolic Diseases Immunological Diseases
摘要: 肠道菌群除了参与机体的消化和营养物质吸收外,还在代谢、免疫调节等过程中发挥重要生理功能。在多种相关疾病患者体内,肠道菌群组成和含量发生显著改变。肠道菌群可以影响宿主的代谢过程,并参与包括肥胖症、二型糖尿病在内的多种代谢疾病。肠道菌群可以通过其代谢产物影响宿主的免疫反应和炎症反应,并参与炎症性肠炎和系统性红斑狼疮等病的发病过程。粪菌移植为多种代谢、免疫疾病提供新的治疗方案,多项粪菌移植的临床试验显示出良好治疗效果,但尚存在争议,需要进一步验证和完善。
Abstract: Besides functions in digestion and nutrient absorption, microbiota also plays an important role in metabolism and immunological regulation. In many related diseases, there is significant alteration of microbiota in patients compared to healthy controls. Microbiota can affect host metabolism, tak-ing part in pathogenesis of many metabolic diseases including obesity and Type II diabetes. Microbiota can exert immunity and inflammation regulation functions through their metabolites, and participate in pathogenesis of inflammatory bowel disease and systemic lupus erythematosus. Research on Gut-Brain-Axis has discovered microbiota’s function in brain development and cognitive behaviors. Psychobiotics has shown positive effects on mental health. Fecal microbiota transplanta-tion has provided new treatment schemes for many metabolic, immunological and neurological disorders. Many clinical trials of fecal microbiota transplantation have shown promising results for disease management, but are still under debate and need more rigorous testing.
文章引用:孙卓. 肠道菌群在代谢、免疫疾病中作用的研究进展[J]. 自然科学, 2022, 10(6): 949-959. https://doi.org/10.12677/OJNS.2022.106107

参考文献

[1] Gilbert, J.A., et al. (2018) Current Understanding of the Human Microbiome. Nature Medicine, 24, 392-400. [Google Scholar] [CrossRef] [PubMed]
[2] Sender, R., Fuchs, S. and Milo, R. (2016) Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biology, 14, e1002533. [Google Scholar] [CrossRef] [PubMed]
[3] Cryan, J.F., et al. (2019) The Microbiota-Gut-Brain Axis. Phys-iological Reviews, 99, 1877-2013. [Google Scholar] [CrossRef] [PubMed]
[4] Codagnone, M.G., et al. (2019) Programming Bugs: Microbiota and the Developmental Origins of Brain Health and Disease. Biological Psychiatry, 85, 150-163. [Google Scholar] [CrossRef] [PubMed]
[5] Claesson, M.J., et al. (2012) Gut Microbiota Composition Correlates with Diet and Health in the Elderly. Nature, 488, 178-184. [Google Scholar] [CrossRef] [PubMed]
[6] Sandhu, K.V., et al. (2017) Feeding the Microbiota-Gut-Brain Axis: Diet, Microbiome, and Neuropsychiatry. Translational Research, 179, 223-244. [Google Scholar] [CrossRef] [PubMed]
[7] Hugon, P., et al. (2015) A Comprehensive Repertoire of Prokaryotic Species Identified in Human Beings. The Lancet Infectious Diseases, 15, 1211-1219. [Google Scholar] [CrossRef
[8] Li, J. and Jia, H. (2014) An Integrated Catalog of Reference Genes in the Human Gut Microbiome. Nature Biotechnology, 32, 834-841.
[9] Leitão-Gonçalves, R., et al. (2017) Commensal Bacteria and Essential Amino Acids Control Food Choice Behavior and Reproduction. PLOS Biology, 15, e2000862. [Google Scholar] [CrossRef] [PubMed]
[10] Nakazato, M., et al. (2001) A Role for Ghrelin in the Central Regulation of Feeding. Nature, 409, 194-198. [Google Scholar] [CrossRef] [PubMed]
[11] Wren, A.M., et al. (2001) Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes, 50, 2540-2547. [Google Scholar] [CrossRef] [PubMed]
[12] Shah, M. and Vella, A. (2014) Effects of GLP-1 on Appetite and Weight. Reviews in Endocrine and Metabolic Disorders, 15, 181-187. [Google Scholar] [CrossRef] [PubMed]
[13] Karra, E., Chandarana, K. and Batterham, R.L. (2009) The Role of Peptide YY in Appetite Regulation and Obesity. The Journal of Physiology, 587, 19-25. [Google Scholar] [CrossRef] [PubMed]
[14] Tolhurst, G., et al. (2012) Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein- Coupled Receptor FFAR2. Diabetes, 61, 364-371. [Google Scholar] [CrossRef] [PubMed]
[15] Cani, P.D., et al. (2009) Gut Microbiota Fermentation of Prebiotics In-creases Satietogenic and Incretin Gut Peptide Production with Consequences for Appetite Sensation and Glucose Re-sponse after a Meal. The American Journal of Clinical Nutrition, 90, 1236-1243. [Google Scholar] [CrossRef] [PubMed]
[16] Parnell, J.A. and Reimer, R.A. (2009) Weight Loss during Oli-gofructose Supplementation Is Associated with Decreased Ghrelin and Increased Peptide YY in Overweight and Obese Adults. The American Journal of Clinical Nutrition, 89, 1751-1759. [Google Scholar] [CrossRef] [PubMed]
[17] Lin, H.V., et al. (2012) Butyrate and Propionate Protect against Di-et-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. PLOS ONE, 7, e35240. [Google Scholar] [CrossRef] [PubMed]
[18] Xiong, Y., et al. (2004) Short-Chain Fatty Acids Stimulate Lep-tin Production in Adipocytes through the G Protein- Coupled Receptor GPR41. Proceedings of the National Academy of Sciences of the United States of America, 101, 1045- 1050. [Google Scholar] [CrossRef] [PubMed]
[19] Turnbaugh, P.J., et al. (2006) An Obesity-Associated Gut Micro-biome with Increased Capacity for Energy Harvest. Nature, 444, 1027-1031. [Google Scholar] [CrossRef] [PubMed]
[20] Tims, S., et al. (2013) Microbiota Conservation and BMI Signatures in Adult Monozygotic Twins. The ISME Journal, 7, 707-717. [Google Scholar] [CrossRef] [PubMed]
[21] Gophna, U., Konikoff, T. and Nielsen, H.B. (2017) Oscillospira and Related Bacteria—From Metagenomic Species to Metabolic Features. Environmental Microbiology, 19, 835-841. [Google Scholar] [CrossRef] [PubMed]
[22] Miller, T.L., et al. (1982) Isolation of Methanobrevibacter smithii from Human Feces. Applied and Environmental Microbiology, 43, 227-232. [Google Scholar] [CrossRef] [PubMed]
[23] Ridaura, V.K., et al. (2013) Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. Science, 341, Article ID: 1241214. [Google Scholar] [CrossRef] [PubMed]
[24] Petersen, C., et al. (2019) T Cell-Mediated Regulation of the Micro-biota Protects against Obesity. Science, 365, eaat9351. [Google Scholar] [CrossRef] [PubMed]
[25] Wu, Y., et al. (2019) The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-Brain Axis. Current Protein & Peptide Science, 20, 750-758. [Google Scholar] [CrossRef] [PubMed]
[26] Bäckhed, F., et al. (2004) The Gut Microbiota as an Environmental Factor That Regulates Fat Storage. Proceedings of the National Academy of Sciences of the United States of America, 101, 15718-15723. [Google Scholar] [CrossRef] [PubMed]
[27] Zhong, H., et al. (2019) Distinct Gut Metagenomics and Metapro-teomics Signatures in Prediabetics and Treatment- Naïve Type 2 Diabetics. EBioMedicine, 47, 373-383. [Google Scholar] [CrossRef] [PubMed]
[28] Allin, K.H., et al. (2018) Aberrant Intestinal Microbiota in Indi-viduals with Prediabetes. Diabetologia, 61, 810-820. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, T.J., et al. (2011) Metabolite Profiles and the Risk of De-veloping Diabetes. Nature Medicine, 17, 448-453. [Google Scholar] [CrossRef] [PubMed]
[30] Koh, A., et al. (2018) Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell, 175, 947-961.e17. [Google Scholar] [CrossRef] [PubMed]
[31] Vieira-Silva, S., et al. (2020) Statin Therapy Is Associated with Lower Prevalence of Gut Microbiota Dysbiosis. Nature, 581, 310-315. [Google Scholar] [CrossRef] [PubMed]
[32] Forslund, K., et al. (2015) Disentangling Type 2 Diabetes and Metformin Treatment Signatures in the Human Gut Microbiota. Nature, 528, 262-266. [Google Scholar] [CrossRef] [PubMed]
[33] Wu, H., et al. (2017) Metformin Alters the Gut Microbiome of Individu-als with Treatment-Naive Type 2 Diabetes, Contributing to the Therapeutic Effects of the Drug. Nature Medicine, 23, 850-858. [Google Scholar] [CrossRef] [PubMed]
[34] Bryrup, T., et al. (2019) Metformin-Induced Changes of the Gut Microbiota in Healthy Young Men: Results of a Non- Blinded, One-Armed intervention Study. Diabetologia, 62, 1024-1035. [Google Scholar] [CrossRef] [PubMed]
[35] Cammarota, G., et al. (2015) Randomised Clinical Trial: Faecal Microbiota Transplantation by Colonoscopy vs. Vancomycin for the Treatment of Recurrent Clostridium difficile Infection. Alimentary Pharmacology & Therapeutics, 41, 835-843. [Google Scholar] [CrossRef] [PubMed]
[36] van Nood, E., et al. (2013) Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. The New England Journal of Medicine, 368, 407-415. [Google Scholar] [CrossRef
[37] Hvas, C.L., et al. (2019) Fecal Microbiota Transplantation Is Supe-rior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology, 156, 1324-1332.e3. [Google Scholar] [CrossRef] [PubMed]
[38] Yu, E.W., et al. (2020) Fecal Microbiota Transplantation for the Improvement of Metabolism in Obesity: The FMT-TRIM Double-Blind Placebo-Controlled Pilot Trial. PLOS Medicine, 17, e1003051. [Google Scholar] [CrossRef] [PubMed]
[39] Vermeire, S., et al. (2016) Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 10, 387-394. [Google Scholar] [CrossRef] [PubMed]
[40] Nicco, C., et al. (2020) From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. Diseases, 8, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[41] Paramsothy, S., et al. (2015) Donor Recruitment for Fecal Microbio-ta Transplantation. Inflammatory Bowel Diseases, 21, 1600-1606. [Google Scholar] [CrossRef
[42] Costello, S.P., et al. (2015) Faecal Microbiota Transplant for Recurrent Clostridium difficile Infection Using Long- Term Frozen Stool Is Effective: Clinical Efficacy and Bacterial Via-bility Data. Alimentary Pharmacology & Therapeutics, 42, 1011-1018. [Google Scholar] [CrossRef] [PubMed]
[43] Youngster, I., et al. (2014) Fecal Microbiota Transplant for Relapsing Clos-tridium difficile Infection Using a Frozen Inoculum from Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study. Clinical Infectious Diseases, 58, 1515-1522. [Google Scholar] [CrossRef] [PubMed]
[44] Cammarota, G., Ianiro, G. and Gasbarrini, A. (2014) Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. Journal of Clinical Gastroenterology, 48, 693-702. [Google Scholar] [CrossRef
[45] Postigo, R. and Kim, J.H. (2012) Colonoscopic versus Nasogastric Fecal Transplantation for the Treatment of Clostridium difficile Infection: A Review and Pooled Analysis. Infection, 40, 643-648. [Google Scholar] [CrossRef] [PubMed]
[46] Cammarota, G., et al. (2015) Decrease in Surgery for Clostridium difficile Infection after Starting a Program to Transplant Fecal Microbiota. Annals of Internal Medicine, 163, 487-488. [Google Scholar] [CrossRef
[47] Vindigni, S.M. and Surawicz, C.M. (2017) Fecal Microbiota Transplanta-tion. Gastroenterology Clinics of North America, 46, 171-185. [Google Scholar] [CrossRef] [PubMed]
[48] Cammarota, G., et al. (2019) International Consensus Conference on Stool Banking for Faecal Microbiota Transplantation in Clinical Practice. Gut, 68, 2111-2121. [Google Scholar] [CrossRef] [PubMed]
[49] Goldenberg, S.D., et al. (2018) Comparison of Different Strate-gies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infectious Diseases and Therapy, 7, 71-86. [Google Scholar] [CrossRef] [PubMed]
[50] DeFilipp, Z., et al. (2019) Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. The New England Journal of Medicine, 381, 2043-2050. [Google Scholar] [CrossRef
[51] Vrieze, A., et al. (2012) Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome. Gastroenterology, 143, 913-916.e7. [Google Scholar] [CrossRef] [PubMed]
[52] Kootte, R.S., et al. (2017) Improvement of Insulin Sensitivity af-ter Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 26, 611-619.e6.
[53] Ng, S.C. and Xu, Z. (2021) Microbiota Engraftment after Faecal Microbiota Transplantation in Obese Subjects with Type 2 Diabetes: A 24-Week, Double-Blind, Randomised Controlled Trial. Gut, 71, 716-723. [Google Scholar] [CrossRef] [PubMed]
[54] Rinott, E., et al. (2021) Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology, 160, 158-173.e10. [Google Scholar] [CrossRef] [PubMed]
[55] de Groot, P., et al. (2021) Faecal Microbiota Transplantation Halts Progression of Human New-Onset Type 1 Diabetes in a Randomised Controlled Trial. Gut, 70, 92-105. [Google Scholar] [CrossRef] [PubMed]
[56] Witjes, J.J., et al. (2020) Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals with Steatohepatitis. Hepatology Communications, 4, 1578-1590. [Google Scholar] [CrossRef] [PubMed]
[57] Abt, M.C., et al. (2012) Commensal Bacteria Calibrate the Ac-tivation Threshold of Innate Antiviral Immunity. Immunity, 37, 158-170. [Google Scholar] [CrossRef] [PubMed]
[58] Rosser, E.C., et al. (2014) Regulatory B Cells Are Induced by Gut Microbiota-Driven Interleukin-1β and Interleukin-6 Production. Nature Medicine, 20, 1334-1339. [Google Scholar] [CrossRef] [PubMed]
[59] Tailford, L.E., et al. (2015) Mucin Glycan Foraging in the Human Gut Mi-crobiome. Frontiers in Genetics, 6, Article No. 81. [Google Scholar] [CrossRef] [PubMed]
[60] Hotamisligil, G.S., Inflammation and Metabolic Disorders. Nature, 444, 860-867.[CrossRef] [PubMed]
[61] Cani, P.D., et al. (2007) Selective Increases of Bifidobacteria in Gut Microflora Improve High-Fat-Diet-Induced Diabetes in Mice through a Mechanism Associated with Endotoxaemia. Diabetologia, 50, 2374-2383. [Google Scholar] [CrossRef] [PubMed]
[62] Wexler, A.G. and Goodman, A.L. (2017) An Insider’s Perspec-tive: Bacteroides as a Window into the Microbiome. Nature Microbiology, 2, Article No. 17026. [Google Scholar] [CrossRef] [PubMed]
[63] Ramakrishna, C., et al. (2019) Bacteroides Fragilis Polysaccharide A Induces IL-10 Secreting B and T Cells That Prevent Viral Encephalitis. Nature Communications, 10, Article No. 2153. [Google Scholar] [CrossRef] [PubMed]
[64] Mishima, Y., et al. (2019) Microbiota Maintain Colonic Homeo-stasis by Activating TLR2/MyD88/PI3K Signaling in IL-10-Producing Regulatory B Cells. Journal of Clinical Investiga-tion, 129, 3702-3716. [Google Scholar] [CrossRef
[65] Mishima, Y., et al. (2015) Resident Bacteria-Stimulated IL-10-Secreting B Cells Ameliorate T Cell-Mediated Colitis by Inducing Tr-1 Cells That Require IL-27-Signaling. Cellular and Molecular Gastroenterology and Hepatology, 1, 295-310. [Google Scholar] [CrossRef] [PubMed]
[66] Round, J.L. and Mazmanian, S.K. (2009) The Gut Microbiota Shapes Intestinal Immune Responses during Health and Disease. Nature Reviews Immunology, 9, 313-323. [Google Scholar] [CrossRef] [PubMed]
[67] Vinolo, M.A., et al. (2011) Regulation of Inflammation by Short Chain Fatty Acids. Nutrients, 3, 858-876. [Google Scholar] [CrossRef] [PubMed]
[68] Koh, A., et al. (2016) From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell, 165, 1332-1345. [Google Scholar] [CrossRef] [PubMed]
[69] Arpaia, N., et al. (2013) Metabolites Produced by Commensal Bac-teria Promote Peripheral Regulatory T-Cell Generation. Nature, 504, 451-455. [Google Scholar] [CrossRef] [PubMed]
[70] Smith, P.M., et al. (2013) The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. Science, 341, 569-573. [Google Scholar] [CrossRef] [PubMed]
[71] Chang, P.V., et al. (2014) The Microbial Metabolite Butyrate Regu-lates Intestinal Macrophage Function via Histone Deacetylase Inhibition. Proceedings of the National Academy of Sci-ences of the United States of America, 111, 2247- 2252. [Google Scholar] [CrossRef] [PubMed]
[72] Wang, Y.D., et al. (2011) The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), Negatively Regulates Hepatic Inflammatory Response through Antagonizing Nuclear Factor κ Light-Chain Enhancer of Activated B Cells (NF-κB) in Mice. Hepa-tology, 54, 1421-1432. [Google Scholar] [CrossRef] [PubMed]
[73] Biagioli, M. and Carino, A. (2017) The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. The Journal of Immunology, 199, 718-733. [Google Scholar] [CrossRef] [PubMed]
[74] Melhem, H., Kaya, B. and Ayata, C.K. (2019) Metabolite-Sensing G Protein-Coupled Receptors Connect the Diet-Microbiota-Metabolites Axis to Inflammatory Bowel Disease. Cells, 8, Article No. 450. [Google Scholar] [CrossRef] [PubMed]
[75] Kostic, A.D., Xavier, R.J. and Gevers, D. (2014) The Microbiome in In-flammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology, 146, 1489-1499. [Google Scholar] [CrossRef] [PubMed]
[76] Manichanh, C., et al. (2012) The Gut Microbiota in IBD. Nature Reviews Gastroenterology & Hepatology, 9, 599-608. [Google Scholar] [CrossRef] [PubMed]
[77] Martinez, C., et al. (2008) Unstable Composition of the Fecal Mi-crobiota in Ulcerative Colitis during Clinical Remission. American Journal of Gastroenterology, 103, 643-648. [Google Scholar] [CrossRef] [PubMed]
[78] Gevers, D., et al. (2014) The Treatment-Naive Microbiome in New-Onset Crohn’s Disease. Cell Host Microbe, 15, 382-392. [Google Scholar] [CrossRef] [PubMed]
[79] Ohkusa, T., et al. (2003) Induction of Experimental Ulcerative Colitis by Fusobacterium varium Isolated from Colonic Mucosa of Patients with Ulcerative Colitis. Gut, 52, 79-83. [Google Scholar] [CrossRef] [PubMed]
[80] Ohkusa, T., et al. (2009) Commensal Bacteria Can Enter Colonic Epithelial Cells and Induce Proinflammatory Cytokine Secretion: A Possible Pathogenic Mechanism of Ulcerative Colitis. Journal of Medical Microbiology, 58, 535-545. [Google Scholar] [CrossRef] [PubMed]
[81] Martinez-Medina, M., et al. (2009) Molecular Diversity of Esche-richia coli in the Human Gut: New Ecological Evidence Supporting the Role of Adherent-Invasive E. coli (AIEC) in Crohn’s Disease. Inflammatory Bowel Diseases, 15, 872-882. [Google Scholar] [CrossRef] [PubMed]
[82] Santoru, M.L., et al. (2017) Cross Sectional Evaluation of the Gut-Microbiome Metabolome Axis in an Italian Cohort of IBD Pa-tients. Scientific Reports, 7, Article No. 9523. [Google Scholar] [CrossRef] [PubMed]
[83] Frank, D.N., et al. (2011) Disease Phenotype and Genotype Are Associated with Shifts in Intestinal-Associated Microbiota in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 17, 179-184. [Google Scholar] [CrossRef] [PubMed]
[84] Yan, J.B. and Luo, M.M. (2020) The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease. Journal of Immunology Research, 2020, Article ID: 8813558. [Google Scholar] [CrossRef] [PubMed]
[85] Wang, Y., et al. (2019) Induction of Intestinal Th17 Cells by Flagellins from Segmented Filamentous Bacteria. Frontiers in Immunology, 10, Article No. 2750. [Google Scholar] [CrossRef] [PubMed]
[86] Larmonier, C.B., et al. (2015) T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome. BioMed Research International, 2015, Article ID: 504638. [Google Scholar] [CrossRef] [PubMed]
[87] Paramsothy, S., et al. (2017) Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn’s and Colitis, 11, 1180-1199. [Google Scholar] [CrossRef] [PubMed]
[88] Narula, N., et al. (2017) Systematic Review and Me-ta-Analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflammatory Bowel Diseases, 23, 1702-1709. [Google Scholar] [CrossRef
[89] Shi, Y., et al. (2016) Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLOS ONE, 11, e0157259. [Google Scholar] [CrossRef] [PubMed]
[90] Zhang, T., et al. (2021) The Potential of Akkermansia mucini-phila in Inflammatory Bowel Disease. Applied Microbiology and Biotechnology, 105, 5785-5794. [Google Scholar] [CrossRef] [PubMed]
[91] He, Z., et al. (2016) Alterations of the Gut Microbiome in Chi-nese Patients with Systemic Lupus Erythematosus. Gut Pathogens, 8, Article No. 64. [Google Scholar] [CrossRef] [PubMed]
[92] van der Meulen, T.A., et al. (2019) Shared Gut, but Distinct Oral Microbiota Composition in Primary Sjögren’s Syndrome and Systemic Lupus Erythematosus. Journal of Autoimmunity, 97, 77-87. [Google Scholar] [CrossRef] [PubMed]
[93] Hevia, A., et al. (2014) Intestinal Dysbiosis Associated with Sys-temic Lupus Erythematosus. mBio, 5, e01548-14. [Google Scholar] [CrossRef
[94] Rodríguez-Carrio, J., et al. (2017) Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus. Frontiers in Im-munology, 8, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[95] Manfredo Vieira, S. and Hiltensperger, M. (2018) Translocation of a Gut Pathobiont Drives Autoimmunity in Mice and Humans. Science, 359, 1156-1161. [Google Scholar] [CrossRef] [PubMed]
[96] Liu, Y., Alookaran, J.J. and Rhoads, J.M. (2018) Probiotics in Auto-immune and Inflammatory Disorders. Nutrients, 10, Article No. 1537. [Google Scholar] [CrossRef] [PubMed]
[97] Esmaeili, S.A., et al. (2017) Tolerogenic Probiotics: Potential Immuno-regulators in Systemic Lupus Erythematosus. Jour- nal of Cellular Physiology, 232, 1994-2007. [Google Scholar] [CrossRef] [PubMed]
[98] Yeh, Y.L., et al. (2021) Heat-Killed Lactobacillus reuteri GMNL-263 In-hibits Systemic Lupus Erythematosus-Induced Cardiomyopathy in NZB/W F1 Mice. Probiotics and Antimicrobial Pro-teins, 13, 51-59. [Google Scholar] [CrossRef] [PubMed]
[99] Khorasani, S. and Mahmoudi, M. (2019) Amelioration of Regu-latory T Cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in Pristane-Induced Lupus Mice Model. Jour-nal of Cellular Physiology, 234, 9778-9786. [Google Scholar] [CrossRef] [PubMed]
[100] de la Visitación, N., Robles-Vera, I. and Toral, M. (2020) Lactobacillus fermentum CECT5716 Prevents Renal Damage in the NZBWF1 Mouse Model of Systemic Lupus Erythematosus. Food & Function, 11, 5266-5274. [Google Scholar] [CrossRef
[101] Toral, M., et al. (2019) Lactobacillus fermentum CECT5716: A Novel Alternative for the Prevention of Vascular Disorders in a Mouse Model of Systemic Lupus Erythematosus. The FASEB Journal, 33, 10005-10018. [Google Scholar] [CrossRef
[102] Liu, R., et al. (2017) Gut Microbiome and Serum Metabolome Alter-ations in Obesity and after Weight-Loss Intervention. Nature Medicine, 23, 859-868. [Google Scholar] [CrossRef] [PubMed]
[103] Gurung, M., et al. (2020) Role of Gut Microbiota in Type 2 Diabetes Patho-physiology. EBioMedicine, 51, Article ID: 102590. [Google Scholar] [CrossRef] [PubMed]
[104] Kudelka, M.R., et al. (2020) Intestinal Epithelial Glycosylation in Homeostasis and Gut Microbiota Interactions in IBD. Nature Reviews Gastroenterology & Hepatology, 17, 597-617. [Google Scholar] [CrossRef] [PubMed]
[105] Gupta, A. and Osadchiy, V. (2020) Brain-Gut-Microbiome Interactions in Obesity and Food Addiction. Nature Reviews Gastroen-terology & Hepatology, 17, 655-672. [Google Scholar] [CrossRef] [PubMed]
[106] Quigley, E.M.M. (2017) Gut Microbiome as a Clinical Tool in Gastrointestinal Disease Management: Are We There Yet? Nature Reviews Gas-troenterology & Hepatology, 14, 315-320. [Google Scholar] [CrossRef] [PubMed]
[107] Wu, G.D., et al. (2016) Comparative Metabolomics in Vegans and Omnivores Reveal Constraints on Diet-Dependent Gut Microbiota Metabolite Production. Gut, 65, 63-72. [Google Scholar] [CrossRef] [PubMed]
[108] Devkota, S. (2016) MICROBIOME. Prescription Drugs Obscure Microbiome Analyses. Science, 351, 452-453. [Google Scholar] [CrossRef] [PubMed]